Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419081
Status:
TERMINATED
Last Update Posted:
2012-01-23
First Post:
2007-01-05
Brief Title:
Study of Forodesine Hydrochloride in Patients With RelapsedRefractory Precursor T-Lymphoblastic LeukemiaLymphoma Who Have Failed Two or More Prior Treatment Regimens
Sponsor:
BioCryst Pharmaceuticals
Organization:
BioCryst Pharmaceuticals
Study Overview
Official Title:
A Phase IIb Multicenter Open-Label Nonrandomized Repeat-Dose Study of Forodesine Hydrochloride in Patients With RelapsedRefractory Precursor T-Lymphoblastic LeukemiaLymphoma Who Have Failed Two or More Prior Treatment Regimens
Status:
TERMINATED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Issues with Manufacturing
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsedrefractory precursor T-Lymphoblastic LeukemiaLymphoma who have failed two or more prior treatment regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None